

Amendments to the Claims:

124. (previously presented) A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulphydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein (a) the apparent molecular weight of the conjugate, as determined by size exclusion chromatography, is at least about 500 kD, and (b) the average actual molecular weight of each nonproteinaceous polymer molecule is at least 20 kD, and wherein the antibody fragment comprises an antigen binding site for a polypeptide selected from the group consisting of: human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human Apo-2 receptor, human tumor necrosis factor- α (TNF- α), human tissue factor (TF), human α 4 β 7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α -chain (TAC).

125. (previously presented) The conjugate of claim 124 wherein the nonproteinaceous polymer molecule is polyethylene glycol (PEG).

126. (currently amended) The conjugate of claim 125 wherein the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and F(ab')₂.

127. (currently amended) The conjugate of claim 125 wherein the antibody fragment is selected from the group consisting of Fab, Fab' and Fab'-SH modified by one PEG molecule.

128. (previously presented) The conjugate of claim 127 wherein the PEG molecule has an average molecular weight of at least 30 kD.

129. (previously presented) The conjugate of claim 124 wherein the apparent molecular weight of the conjugate is at least about 800 kD.

130. (previously presented) The conjugate of claim 124 wherein the apparent molecular weight of the conjugate is at least about 1,800 kD.

131. (previously presented) The conjugate of claim 124 comprising the antigen binding site of HER2.

132. (currently amended) The conjugate of claim 124 comprising the antigen binding site of DC20 CD20.